Latest News

June 22, 2022

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

June 20, 2022

TMIST breast cancer trial looks to recruit underserved communities

June 8, 2022

Dr. Abhishek Tripathi discusses the 8-year survival outcomes from the CHAARTED trial for patients with advanced prostate cancer

June 7, 2022

Pancreatic neuroendocrine tumors: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

June 7, 2022

E2108 evidence informs a discussion on systemic therapy vs surgery for de novo stage IV breast cancer

June 6, 2022

Novel drug combination demonstrates promising results in treating pancreatic neuroendocrine tumors

June 6, 2022

E2211: Dr. Pamela Kunz discusses the trial results and talks about the challenges of managing endocrine tumors

June 6, 2022

Dr. Michael Atkins discusses the DREAMseq trial in patients with advanced melanoma

June 5, 2022

Dr. Pamela Kunz on pancreatic neuroendocrine tumors: A final analysis of temozolomide or temozolomide plus capecitabine


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
43

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group